VYNE Therapeutics (NASDAQ:VYNE) Stock Rating Reaffirmed by HC Wainwright

VYNE Therapeutics (NASDAQ:VYNE)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They presently have a $5.75 target price on the stock. HC Wainwright’s price target would suggest a potential upside of 98.96% from the stock’s current price.

VYNE Therapeutics Price Performance

Shares of NASDAQ VYNE opened at $2.89 on Monday. The business’s fifty day moving average price is $2.50 and its 200-day moving average price is $2.59. VYNE Therapeutics has a one year low of $1.67 and a one year high of $8.73. The stock has a market capitalization of $40.75 million, a PE ratio of -0.41 and a beta of 1.26.

VYNE Therapeutics (NASDAQ:VYNE) last announced its quarterly earnings results on Thursday, February 29th. The company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.30. VYNE Therapeutics had a negative net margin of 6,710.38% and a negative return on equity of 77.46%. The company had revenue of $0.08 million for the quarter, compared to analysts’ expectations of $0.15 million. As a group, equities analysts expect that VYNE Therapeutics will post -1 EPS for the current fiscal year.

Institutional Investors Weigh In On VYNE Therapeutics

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Parkman Healthcare Partners LLC purchased a new stake in shares of VYNE Therapeutics Inc. (NASDAQ:VYNE) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 696,470 shares of the company’s stock, valued at approximately $1,623,000. Parkman Healthcare Partners LLC owned approximately 4.99% of VYNE Therapeutics at the end of the most recent reporting period. 83.78% of the stock is currently owned by institutional investors and hedge funds.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.